Novartis AG logo

NOVN - Novartis AG News Story

CHF80.49 0.4  0.6%

Last Trade - 14/05/21

Sector
Healthcare
Size
Large Cap
Market Cap £142.27bn
Enterprise Value £166.24bn
Revenue £35.39bn
Position in Universe 4th / 1053

BRIEF-Novartis says Kesimpta showed reduction in disability progression in patients newly diagnosed with relapsing MS

Fri 16th April, 2021 6:22am
April 16 (Reuters) - Novartis AG  NOVN.S :
    * NOVARTIS ANNOUNCED TODAY NEW POST HOC DATA FROM PHASE III
ASCLEPIOS TRIALS
    * KESIMPTA® (OFATUMUMAB) DATA AT AAN SHOWED REDUCTION IN
DISABILITY PROGRESSION INDEPENDENT OF RELAPSE ACTIVITY IN NEWLY
DIAGNOSED PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS
(RMS)

Source text for Eikon:  ID: 
Further company coverage:  NOVN.S 

 (Reporting by John Revill)
 ((John.Revill@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.